Sign in
CompletedPhase 1

A Phase 1, First-in-human Study of VX-668

Key facts

Who runs it
Vertex Pharmaceuticals Incorporated
Where
Gainesville, Lenexa, Orlando, Salt Lake City, and Tempe, United StatesSee the 5 sites
Trial code
Status
Completed
Phase
Phase 1
People taking part
114 people enrolled
Started
8 Feb 2023
Ended
13 Feb 2024
Type of study
Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • VX-668
  • Placebo
Record updated
15 March 2024

Who can take part

Age
18 years to 55 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Participants of age between 18 to 55 years (inclusive)
  • Body mass index (BMI) of 18.0 to 32.0 kilogram per meter square (kg/m\^2)
  • A total body weight of more than (>)50 kg
  • Nonsmoker or ex-smoker for at least 3 months before screening

Who cannot take part

  • Any condition possibly affecting drug absorption
  • Females of childbearing potential; Other protocol defined Inclusion/Exclusion criteria may apply

Where in United States

  • University of FloridaGainesville, United States
  • ICON LenexaLenexa, United States
  • Central Florida Pulmonary Group, P.A.Orlando, United States
  • ICON-Salt Lake CitySalt Lake City, United States
  • Celerion - TempeTempe, United States

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of VX-668 at various doses.

The 4 groups in the trial

  • Part ATreatment being tested

    Participants grouped in different cohorts will receive a single ascending dose of VX-668.

    Treatment: VX-668

  • Placebo Part APlacebo, for comparison

    Participants will be randomized to receive placebo matched to VX-668.

    Treatment: Placebo

  • Part BTreatment being tested

    Participants grouped in different cohorts will receive multiple doses of VX-668.The dose levels will be determined based on the data from Part A.

    Treatment: VX-668

  • Placebo Part BPlacebo, for comparison

    Participants will be randomized to receive placebo matched to VX-668.

    Treatment: Placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 1, First-in-human Study of Safety, Tolerability, and Pharmacokinetics of VX-668
Record updated
15 March 2024